BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) has officially changed its English company name from “BeiGene, Ltd.” to “BeOne Medicines Ltd.” effective May 27, 2025 (Swiss Time). According to the announcement, the Registrar of Companies in Hong Kong issued the Certificate of Registration of Alternation of Name on October 2, 2025, confirming the new English name registration under Part 16 of the Companies Ordinance (Cap. 622 of the Laws of Hong Kong).

Following this change, the English stock short name on the Hong Kong Stock Exchange will be updated from “BEIGENE” to “BEONE MEDICINES” at 9:00 a.m. on Wednesday, October 22, 2025 (Hong Kong Time). The Chinese stock short name remains “百濟神州,” and the stock code remains “06160.”

As of the date of the announcement, the Board of Directors comprises Chairman and Executive Director Mr. John V. Oyler, Non-executive Director Dr. Xiaodong Wang, and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp, and Mr. Qingqing Yi. The announcement is dated October 17, 2025.